Topiramate Dosing Guidelines
Start topiramate at 25 mg daily and titrate by 25 mg weekly to a target dose of 100-150 mg daily in divided doses for most indications, with dose adjustments required for renal impairment (reduce dose by 50% if creatinine clearance <70 mL/min/1.73m²). 1
Adult Dosing by Indication
Epilepsy - Monotherapy
- Starting dose: 25 mg twice daily (50 mg/day)
- Titration schedule:
- Week 1: 25 mg twice daily
- Week 2: 50 mg twice daily
- Week 3: 75 mg twice daily
- Week 4: 100 mg twice daily
- Week 5: 150 mg twice daily
- Week 6: 200 mg twice daily (target dose: 400 mg/day)
- Maximum dose: 400 mg/day in two divided doses 1
Epilepsy - Adjunctive Therapy
- Starting dose: 25-50 mg/day
- Titration: Increase by 25-50 mg/week
- Target dose: 200-400 mg/day in two divided doses for partial seizures; 400 mg/day for primary generalized tonic-clonic seizures 1
- Maximum studied: 1,600 mg/day (though doses above 400 mg/day show no additional benefit) 1
Migraine Prophylaxis (Adults)
- Starting dose: 25 mg daily
- Titration: Increase by 25 mg weekly
- Target dose: 100-150 mg daily in divided doses 2, 3
- The 2025 ACP guideline recommends topiramate as one option for episodic migraine prevention (1-14 headache days/month), though notes this is conditional recommendation with low-certainty evidence 3. Clinical trials demonstrate significant efficacy at 100 mg/day and 200 mg/day, with onset of preventive action within the first month 4.
Obesity Management (Phentermine-Topiramate ER)
- Starting dose: 3.75 mg phentermine/23 mg topiramate once daily for 14 days
- Maintenance dose: 7.5 mg/46 mg daily
- Escalation (if needed after 12 weeks): 11.25 mg/69 mg for 14 days, then 15 mg/92 mg daily
- Target dose: 15 mg/92 mg daily (maximum dose) 5
- Discontinue if <3% weight loss at 12 weeks on 7.5/46 mg, or <5% weight loss at 12 weeks on maximum dose 5
Cyclic Vomiting Syndrome (CVS) Prophylaxis
- Starting dose: 25 mg daily
- Titration: Increase by 25 mg each week
- Target dose: 100-150 mg daily in divided doses 2
- Monitor serum electrolytes and renal function twice annually 2
Nightmare Disorder/PTSD
- Starting dose: 12.5-25 mg daily (or 25 mg/day)
- Titration: Increase by 25-50 mg every 3-4 days
- Target dose: 100 mg/day or less for most responders (91% of full responders)
- Range: 12.5-500 mg/day; median effective dose 150 mg/day 6
Pediatric Dosing
Epilepsy - Monotherapy (≥10 years)
- Same as adult dosing: target 400 mg/day in two divided doses 1
Epilepsy - Adjunctive Therapy (Ages 2-16 years)
- Starting dose: 25 mg (or 1-3 mg/kg/day) nightly for first week
- Titration: Increase by 1-3 mg/kg/day at 1-2 week intervals
- Target dose: 5-9 mg/kg/day in two divided doses 1
Migraine Prophylaxis (Pediatric/Adolescent)
- Recommended dose: 2 mg/kg/day (up to adult dose of 100 mg/day) 7, 8
- Studies show doses <2 mg/kg/day (mean 1.2 mg/kg/day) are effective and well-tolerated 9
- FDA approval: Ages 12-17 years for migraine prevention 8
- Important caveat: A large multicenter RCT was stopped early showing no benefit over placebo, though smaller studies support effectiveness 8. The 2020 AAN guideline recommends discussing with families that placebo was as effective as topiramate in many trials 7.
Dose Adjustments for Renal Impairment
Critical adjustment required: Topiramate clearance is significantly reduced in renal impairment 1, 10.
Moderate Renal Impairment (CrCl 30-69 mL/min/1.73m²)
Severe Renal Impairment (CrCl <30 mL/min/1.73m²)
End-Stage Renal Disease (ESRD) on Hemodialysis
- Reduce dose by 50% 1, 10
- Supplemental dose required: Hemodialysis removes significant topiramate (dialysis clearance 120-123.5 mL/min vs. normal clearance 20-30 mL/min) 1, 10
- Longer time to reach steady-state at each dose 1
Dose Adjustments for Hepatic Impairment
Minimal adjustment needed: Topiramate clearance may decrease in hepatic impairment, but the mechanism is unclear 1.
Moderate-Severe Hepatic Impairment
- Small increase (29%) in peak concentrations and AUC observed 10
- Dose adjustments might not be required, though monitor closely 10
- The small sample size in studies limits generalization 10
Elderly Patients (≥65 years)
- Dosage adjustment indicated when renal function is impaired (CrCl ≤70 mL/min/1.73m²) 1
- Elderly patients have 21% reduced clearance and 19% reduced renal clearance compared to young adults 1
- Monitor renal function in elderly patients 1
Critical Monitoring Requirements
Mandatory Monitoring
- Serum electrolytes and renal function: Monitor twice annually, especially with higher doses 2, 5
- Pregnancy tests: Monthly monitoring for women of childbearing potential (topiramate is teratogenic) 5
- Serum bicarbonate: Periodic monitoring for long-term use due to carbonic anhydrase inhibitor properties 5
Clinical Monitoring
- Blood pressure and heart rate: When used in phentermine-topiramate combination 5
- Liver enzymes: When used with coenzyme Q10 2
Important Clinical Considerations
Contraindications and Cautions
- Avoid in patients with history of kidney stones (increased risk due to metabolic acidosis, hypercalciuria, hypocitraturia) 2, 5
- Pregnancy: Absolutely contraindicated - topiramate is teratogenic. Require effective contraception 5
- Cardiovascular disease/uncontrolled hypertension: Avoid phentermine-topiramate combination 5
- Untreated hyperthyroidism: Avoid phentermine-containing products 5
Discontinuation Protocol
- Taper required: Take capsule every other day for at least 1 week before stopping to minimize seizure risk 5
Timing of Administration
- Take early in the day to minimize insomnia risk (especially phentermine-topiramate) 5
- Can be taken without regard to meals 1
- Do not break tablets due to bitter taste 1
Common Adverse Effects (Dose-Related)
- Paresthesias (most common)
- Cognitive dysfunction, difficulty with concentration/attention, memory problems
- Weight loss (may be advantageous in obesity)
- Nausea, fatigue, dizziness
- Mood problems, depression, nervousness 2, 6, 11